Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We recently demonstrated a positive effect of berberine on nonalcoholic fatty liver disease patients after 16 weeks of treatment by comparing mere lifestyle intervention in type 2 diabetes patients with berberine treatment, which decreased the content of hepatic fat. However, the potential mechanisms of the clinical effects are unclear. We used a lipidomic approach to characterize the state of lipid metabolism as reflected in the circulation of subjects with nonalcoholic fatty liver disease (NAFLD) before and after berberine treatment. METHODS: Liquid chromatography-mass spectrometry evaluated the various lipid metabolites in serum samples obtained from the participants (41 patients in the berberine group and 39 patients in the mere lifestyle intervention group) before and after treatment. RESULTS: A total of 256 serum lipid molecular species were identified and quantified. Both treatments regulated various types of lipids in metabolic pathways, such as free fatty acids, phosphoglycerides and glycerides, in metabolic pathways, but berberine induced a substantially greater change in serum lipid species compared with mere lifestyle intervention after treatment. Berberine also caused obvious differences on ceramides. Berberine treatment markedly decreased serum levels of ceramide and ceramide-1-phosphate. CONCLUSIONS: Berberine altered circulating ceramides, which may underlie the improvement in fatty liver disease. ClinicalTrials.gov NCT00633282, Registered March 3, 2008.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Self-citationA lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338 · cited 3×
“Abbreviations BBR: berberine; TC: total cholesterol; TG: triglyceride; LDL-c: low-density lipoprotein; NAFLD: nonalcoholic fatty liver disease; DG: diacylglycerol; PC: phosphatidylcholine; PUFAs: polyunsaturated fatty acids; NASH: nonalcoholic steatohepatitis; IGR: impaired glucose regulation; LSI: lifestyle intervati…”
Backgroundon behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“LSI (including dietary modification and exercise) was performed following standardized recommendations [13].”
MethodThe plasma lipidomic signature of nonalcoholic steatohepatitis
Puri, P., Wiest, M. M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H., Contos, M. J., Sterling, R. K., Fuchs, M., Zhou, H., et al. (2009) · Hepatology · doi:10.1002/hep.23229 · Cited by 655 · cited 2×
“The lipogenic activity levels off or declines modestly with progression to nonalcoholic steatohepatitis (NASH), but lipoxygenase (LOX) activity increases [11].”
BackgroundTreatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573 · cited 4×
“BBR significantly lowered fasting blood glucose (FBG), hemoglobin A1C, triglyceride, and insulin levels in patients with type 2 diabetes mellitus (T2DM) in the clinical study [7].”
BackgroundResultInfluentialSphingolipids and insulin resistance: the five Ws
Summers, S. A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283373b66 · Cited by 136
Wang, M., Wang, F., Wang, Y., Ma, X., Zhao, M., & Zhao, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078731 · Cited by 66
Cited by
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, S. T. S., Šmejkal, K., Malaník, M., et al. (2019) · Theranostics · doi:10.7150/thno.30787 · Cited by 465
Berberine and barberry (Berberis vulgaris): A clinical review
Imenshahidi, M., & Hosseinzadeh, H. (2019) · Phytotherapy Research · doi:10.1002/ptr.6252 · Cited by 368
Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway
Zhu, X., Bian, H., Wang, L., Sun, X., Xu, X., Yan, H., Xia, M., Chang, X., Lu, Y., Li, Y., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.06.019 · Cited by 273
Self-citationBerberine as a potential autophagy modulator
Mohammadinejad, R., Ahmadi, Z., Tavakol, S., & Ashrafizadeh, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28325 · Cited by 132
Metadata
- Authors
- Chang, X., Wang, Z., Zhang, J., Yan, H., Bian, H., Xia, M., Lin, H., Jiang, J., & Gao, X.
- Venue
- Journal of Translational Medicine
- Published
- 2016-09-15
- Volume
- 14
- Issue
- 1
- Pages
- 266-266
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2519563366
- Cited by
- 96
- References
- 7
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. https://app.cochat.ai/papers/10.1186/s12967-016-0982-x
- The paper
- Chang, X., Wang, Z., Zhang, J., Yan, H., Bian, H., Xia, M., Lin, H., Jiang, J., & Gao, X. (2016). Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. Journal of Translational Medicine. https://doi.org/10.1186/s12967-016-0982-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.